The urinary excretion of uric acid in individuals with primary gout has been shown to be approximately the same as, or in a minority of instances greater than, that of normal subjects on comparable diets (2, 3). These observations, plus the failure to demonstrate significant differences in the renal clearance of uric acid in gouty and nongouty control subjects, have led to the conclusion that patients with gout excrete uric acid in a normal manner (2-5).
IMPAIRMENT OF URIC ACID EXCRETION IN GOUT
The urinary excretion of uric acid in individuals with primary gout has been shown to be approximately the same as, or in a minority of instances greater than, that of normal subjects on comparable diets (2, 3) . These observations, plus the failure to demonstrate significant differences in the renal clearance of uric acid in gouty and nongouty control subjects, have led to the conclusion that patients with gout excrete uric acid in a normal manner (2) (3) (4) (5) .
This view has, however, recently been challenged (6) on the ground that in the studies on which it was based, differences in the plasma urate concentrations of gouty and nongouty subjects were not taken into account. In order to eliminate such differences Nugent and Tyler (6) induced hyperuricemia in nongouty individuals by the oral administration of uric acid precursors and compared uric acid excretion in these subjects and patients with gout. Under these conditions an impairment in urate excretion was clearly evident in patients with gout; both the excretion and clearance of urate were significantly less than in nongouty subjects with equivalent plasma urate levels.
These observations of impaired uric acid excretion were fully supported by the present study, in which urate was administered intravenously to gouty and nongouty subjects in order to a) study urate excretion at equivalent and various plasma levels and b) examine the dynamics of the renal tubular transfer mechanisms for urate. (1) .
METHODS
The urinary excretion and renal clearance of uric acid were determined in 10 nongouty control subjects and in 11 patients with primary gout. The nongouty subjects, all but two of whom (M.W. and D.B.) were males, varied in age from 33 to 65 years and were free of apparent renal, hematologic, cardiovascular, or endocrine disease. The serum uric acid concentration was normal in all of the nongouty subjects, varying in the group from 3.1 to 5.5 mg per 100 ml. The pertinent clinical features of the patients with gout, all but one of whom (A.C.) were males, are shown in Table I . All of the patients had elevated serum uric acid levels (Table II) and a history consistent with gouty arthritis. None had clinical or laboratory evidence of renal or hematologic disease, renal calculi, or cardiac failure. Three of the patients with gout (S.M., N.T., and B.P.) had been treated with probenecid. Medication was discontinued in these individuals 16 days, 5 days, and 24 hours, respectively, prior to the test. The remaining patients had received no uricosuric medication.
All subjects were allowed their usual ad lib diets. After an overnight fast each subject ingested 500 ml of water approximately one hour before the test. During the experiment water was given orally at 15-to 30-minute intervals as needed to replace urinary losses. Urine was collected through a urethral catheter, and arterial blood from an indwelling needle placed in the brachial artery. After the collection of from one to three 15-to 20-minute control clearance periods, a priming injection of 25 ml of inulin was given and an intravenous infusion containing lithium urate and inulin was started. The infusion was prepared by dissolving 4.0 g of uric acid in 1 L of hot 0.15 per cent lithium carbonate solution. After the solution had cooled, 50 ml of inulin and 15 ml of 50 per cent glucose were added. The infusion was given at a rate of 4.5 ml per minute for 90 to 120 minutes and was then increased to a rate of 8.0 ml per minute for an additional 60 to 90 minutes. All subjects tolerated the infusion well except for one control subject who became nauseated at the conclusion of the test.
During the infusion of lithium urate 8 to 14 clearance periods, each 10 to 20 minutes in duration, were obtained. A sample of arterial blood was collected at approximately the mid-point of each period and was mixed with heparin and centrifuged immediately. Urine was collected by standard renal clearance procedures.
Analysis of plasma and urine was usually made on the day of the test. Occasionally the samples were re- Table III . The infusion of lithium urate resulted in a progressive increase in plasma urate concentration, uric acid excretion and clearance, and in the urate/inulin clearance ratio. The changes in plasma urate concentration were equivalent, and the maximal level attained was approximately the same in the two subjects. However, the changes in uric acid excretion and clearance and in the urate/inulin clearance ratio with each increment in plasma level and filtered load were greater in the nongouty than in the gouty subject. Moreover, at equivalent plasma levels and filtered loads, the excretion and clearance of uric acid and the urate/inulin clearance ratios were significantly higher in the nongouty than in the gouty subject.
Similar differences were found in all of the patients with gout studied with the possible exception of patient C.E., in whom the results were equivocal. Figures 1 and 2 summarize the results in all ten nongouty subjects and the eleven patients with gout. In Figure 1 the urate/inulin clearance ratio is plotted against the plasma urate concentration. In Figure 2 this ratio is plotted as a function of the filtered urate load. These figures show that the urate/inulin clearance ratio was distinctly less in gouty subjects than in nongouty subjects when compared at equivalent plasma levels and filtered loads. In most patients this difference was evident at all levels and loads obtained, but was more pronounced at higher concentrations and loads. In gouty patients F. approximately 12 mg per 100 ml. At higher concentrations and at all filtered loads a distinct reduction in the clearance ratio was apparent. In gouty patient C.E. a reduced clearance ratio was evident at low plasma urate concentrations (below 10 mg per 100 ml) and loads, but at higher levels the clearance ratio was not significantly different from the values in nongouty subjects. In this subject, therefore, the evidence of impaired urate excretion was equivocal.
Reference to Tables I and II indicates that the reduction in uric acid clearance noted in Figures  1 and 2 was independent of the age of the patient, duration or severity of the disease, the level of 24-hour urinary uric acid excretion (high, patient W.B.; variable, others), the initial plasma uric acid concentration, and the glomerular filtration rate.
Equilibrium dialysis
In order to determine whether the reduced excretion of uric acid was the result of renal mechanisms or of plasma binding of urate, experiments employing equilibrium dialysis were performed with plasma from three (W.H., V.W., and R.Z.) of the gouty subjects studied. The results of one such experiment are shown in Table IV At all plasma levels and filtered loads obtained in gouty and nongouty subjects, the quantity of uric acid excreted was less than that filtered, indicating net tubular reabsorption of uric acid. 2 Representative titration curves of net reabsorption and excretion of uric acid in a nongouty 2 The fact that excretion was less than filtration does not indicate that reabsorption is the only tubular transfer operation involved. If tubular secretion of urate contributes significantly to the process of excretion (11), the differences between filtration and excretion describe only the predominant transfer operation (12) , which in this instance was tubular reabsorption. Figure 3 . These curves were constructed from data presented in Table III over, in five nongouty subjects an apparent maximal net reabsorptive rate (Tm) was demonstrated which varied from 9.78 to 14.30 mg per minute. In contrast, net reabsorption (T) became constant at a maximal rate (14.03 mg per minute) in only one (C.E.) of the patients with gout. Load/T ratios exceeded 1.5 in all but one (S.M.) of the nongouty subjects in whom an apparent Tm was demonstrated, suggesting adequate saturation of reabsorptive capacity. The load,/T ratio in gouty subject C.E. was 1.54; in the remainder of the gouty subjects, load/T ratios were below 1.3.
DISCUSSION
The results of the present study fully support the conclusions of Nugent and Tyler (6) that the renal excretion of uric acid is impaired in patients with primary gout. Under control conditions, in comparison of hyperuricemic gouty subjects with nongouty individuals whose plasma uric acid concentrations are normal, the impairment in uric acid excretion is not readily apparent. The reason for this is that both the excretion and plasma concentration of uric acid tend to be higher under these conditions in gouty subjects than in normal individuals, and hence the renal clearance of urate is approximately the same in the two groups.
Comparison in this way does not, however, take into account the fact that urate excretion and clearance are influenced by the plasma urate concentration, i.e., as the plasma-level increases both excretion and clearance also rise. Thus, under control conditions, a higher renal clearance of urate would be expected in hyperuricemic gouty subjects than in nongouty individuals with normal plasma levels, if there were no disturbance in renal excretory mechanisms. That this difference is not found therefore suggests that renal mechanisms are, in fact, altered in patients with gout.
The demonstration of an alteration in excretory mechanisms becomes conclusive when gouty and nongouty subjects are studied at equivalent plasma urate concentrations. Under such circumstances, when plasma urate levels are increased by the oral administration of ribonucleic acid (6) or by the administration of urate intravenously, as was done in the present study, a distinct impairment of urate excretion and clearance is apparent in individuals with gout.
The demonstration of impaired excretion in all eleven patients in the present study, with the possible exception of subject C.E., suggests that altered excretory function is a characteristic feature of the disease. Impaired excretion was evident in individuals who varied with respect to age, sex, duration and severity of the disease, the initial plasma urate concentration, and the quantity of uric acid excreted in the urine. The fact that impaired excretory function was evident in individuals who excreted both high and normal amounts of urate in the urine under control conditions (Tables I and II) serves to emphasize the widespread occurrence of the excretory disturbance in gout.
By demonstrating an equal distribution of urate between gouty and normal plasma during in vitro dialysis, an alteration in renal mechanisms rather than plasma binding was established as the mechanism of impaired urate excretion in patients with gout. The factors responsible for this alteration in renal function are, however, not known. Two mechanisms may be considered: augmented tubular reabsorption of urate, or decreased tubular secretion.
If we assume a filtration-reabsorption hypothesis as the mechanism of uric acid excretion (13) , the results presented in Tables V and VI and Figure  3 may be interpreted as indicating that both the rate and capacity of tubular reabsorption of urate are augmented in patients with gout. If, on the other hand, urate excretion is conceived of as occurring by a process of tubular secretion (11) , the results of the present study can be explained on the basis of impaired secretory activity. The end result in either instance is the same, a reduction in urate excretion. With the present state of uncertainty concerning the precise mechanisms of urate excretion, there is no way to distinguish between these two possible functional alterations. Although it may be somewhat more comfortable to assume that disease acts by depressing rather than by augmenting function, it would be unwarranted on this ground alone to conclude that the functional alteration in gout involves an impairment of tubular secretion. There are precedents for augmented function in other diseases, and increased reabsorption of urate might develop in gout in a variety of ways. An adaptive response to chronic hyperuricemia, a genetically determined or acquired metabolic alteration in tubular transport activity, or a renal effect of some chemical or hormonal substance may be and have been mentioned (6) as possibilities. Such factors, with the possible exception of adaptation, might also be invoked to account for impairment of tubular secretion, if this can be shown to be the functional disturbance involved. At present, however, the respective roles of reabsorption and secretion are not sufficiently delineated to permit a definitive conclusion concerning the nature of the renal functional alteration in gout.
Despite this impairment of excretory function, a continuously positive balance between urate production and excretion is not necessarily required in patients with gout. As in normal individuals, the renal excretion of urate may be of sufficient magnitude to approximate net urate productionactual production minus extrarenal excretion and degradation (2. 14)-but to the extent that this occurs in patients with gout, it is accomplished by virtue of an elevated plasma urate concentration. In this respect an analogy may be made with urea excretion and equilibrium in individuals with azotemia due to renal failure (10) . These considerations do not, however, establish a primary role for renal factors in the pathogenesis of hyperuricemia in gout. Although impaired excretion may play such a role, this remains to be established. Altered kidney function clearly serves, however, to maintain and contribute to the elevated plasma uric acid levels characteristic of this disease.
SUM MARY
The renal excretion and clearance of uric acid were determined in 10 nongouty subjects and 11 patients with primary gout before and during an intravenous infusion of lithium urate. Under control conditions prior to the infusion, the mean rate of uric acid excretion was somewhat greater and the mean urate/inulin clearance ratio was somewhat less in gouty than in nongouty subjects, but the renal clearance of urate did not differ significantly in the two groups. Under conditions of intravenous urate loading, however, an impairment in uric acid excretion was clearly evident in patients with gout. At equivalent plasma levels and filtered loads, the excretion and clearance of urate and the urate/inulin clearance ratio were significantly less in all of the patients with gout, with one possible exception, than in nongouty control subjects. The demonstration of this functional alteration with such regularity suggested that impaired urate excretion is a characteristic feature of primary gout.
In both gouty and nongouty subjects, the differences between the rates of filtration and excretion of urate during intravenous loading were indicative of net tubular reabsorption of this substance. However, net reabsorption was greater in patients with gout than in nongouty subjects at equivalent filtered loads, and with one exception, was not maximally limited with increasing loads. In contrast, a maximal net reabsorptive rate was demonstrated in five of the nongouty subjects studied.
On the basis of in vitro studies of urate diffusion, plasma binding was excluded as a cause of reduced urate excretion in patients with gout. Impairment of excretion was therefore attributed to an alteration in renal mechanisms. Whether this alteration involved augmented tubular reabsorption of urate or impairment of tubular secretion was not established.
